Indication
Cutaneous T-Cell Non-Hodgkin Lymphoma
4 clinical trials
7 products
2 drugs
Clinical trial
A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell LymphomaStatus: Recruiting, Estimated PCD: 2025-06-01
Drug
AN0025Product
LenalidomideClinical trial
Phase I Study of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Plus Standard BEAM Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Mature T-Cell Non-Hodgkin Lymphoma: the aTAC BEAM RegimenStatus: Active (not recruiting), Estimated PCD: 2020-09-18
Product
Yttrium Y 90 BasiliximabProduct
CarmustineProduct
EtoposideProduct
CytarabineDrug
MelphalanClinical trial
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)Status: Active (not recruiting), Estimated PCD: 2023-08-04
Product
MEDI-570Clinical trial
A Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell LymphomasStatus: Active (not recruiting), Estimated PCD: 2024-04-30
Product
Brentuximab Vedotin